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Abstract
Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly
immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in
establishing eligibility criteria for antifungal trials. There is an important need for generation of
consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success
and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study
Group and the European Organization for Research and Treatment of Cancer was convened to
propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study
outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species,
Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and
Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting
clinical, radiological, and/or mycological data and gaps in knowledge.
Invasive fungal diseases (IFDs) are major causes of morbidity and mortality among highly
immunocompromised patients. The European Organization for Research and Treatment of
Cancer (EORTC) and the Mycoses Study Group (MSG) published guidelines on definitions
of IFDs for clinical research [1,2]. Bennett et al. [3–5] previously discussed challenges in the
design of antifungal trials. Our objective here is to establish consensus criteria for evaluating
therapeutic responses in phase III trials of IFDs.
Although specific criteria for therapeutic success vary for the major IFDs, global response
requires survival and a positive effect on fungal disease (table 1). With certain IFDs (e.g.,
candidemia), cure is the goal of therapy. The term, “documented clearance” is more appropriate
than “sterilization,” because the yield of cultures can vary, especially while patients are
receiving antifungals. In histoplasmosis and cryptococcosis, a response soon after start of
therapy may be termed, “successful control of disease,” correctly implying that cure may not
have been achieved. Indeed, the best proof of cure for these fungal diseases is absence of relapse
after cessation of therapy. The observation period to meet this high standard for certain IFDs
may involve years and would be impractical for therapeutic trials. Therefore, we attempted to
strike a balance between these limitations and practical end points that can be incorporated into
therapeutic trials.
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The primary analysis should include all patients in the intent-to-treat (ITT) or modified intent-
to-treat (MITT) groups. Completion of the assigned treatment regimen is generally a
requirement for a successful outcome. However, it is also reasonable to make provision for
“success with modification,” as was done in a trial that compared voriconazole with
amphotericin B therapy for invasive aspergillosis in which the protocol, in effect, evaluated 2
different treatment regimens rather than 2 different drugs [6,7].
Conflicting Data
Recognizing when primary antifungal therapy fails is often not straightforward, particularly
when data are inadequate or conflicting [8–10]. Protocols should ideally prespecify a rank order
of the weight given to specific categories of data, with more weight generally given to objective
data (e.g., oxygen saturation) than to subjective data (e.g., presence of dyspnea), as well as to
specific signs of fungal diseases (e.g., facial swelling in invasive fungal sinusitis) than to less
specific signs (e.g., fever).
Discordant clinical, radiological, and/or mycological data may result from an inadequate period
of evaluation. Selection of time points for assessment of response should account for the
potential of early conflicting data. A competing concern is that longer periods of evaluation of
response may increase the likelihood of seemingly unrelated events (e.g., relapsed malignancy)
that would confound the interpretation of response to antifungal therapy. Suggested minimum
periods of observation for the major IFDs are included in tables 2–5.
Requirement for Survival
The majority of panel members considered survival through at least the time of assessment of
the primary end point to be necessary, although not sufficient, for a successful outcome.
Because mortality may result from causes seemingly unrelated to the IFD, some panel members
argued that more-direct markers of response to antifungal treatment (e.g., clearance of cultures
or a reduction in the level of a laboratory marker) should be used as primary end points instead
of survival. Prespecified criteria for attributable mortality have been used in some studies of
antifungals [11–13]. Anaissie [14] argued that, in patients with invasive aspergillosis (IA),
deaths for which there is no autopsy evidence of persistent fungal disease should be considered
successful outcomes in trials of antifungal agents.
Attribution of mortality is difficult in patients with medically complex cases [15], even for the
minority for whom autopsies are performed. Drug toxicity may influence survival in ways not
obvious to the investigator (e.g., drug-drug interactions) [16] or at autopsy. In addition, the
interaction of antifungal drugs with host immunity is an area of growing interest [17–23]; such
interactions cannot be encapsulated solely by fungal markers and may influence survival in
ways we do not understand. Randomization is expected to balance the effect of confounding
variables that affect survival in the ITT or MITT analysis.
Candidemia and Other Forms of Invasive Candidiasis
In candidemia, documented clearance of Candida species from the blood should be a
requirement for a successful outcome. Symptoms and signs (e.g., fever) attributable to disease
may persist, but such signs are nonspecific and should not, by themselves, be equated with
failure. Removal of a central line may reduce the time to clearance of blood cultures in cases
of candidemia [24]. However, unless the protocol prespecifies removal of intravenous catheters
as a requirement for eligibility, catheter removal should not be considered in the outcome
assessment. Follow-up sampling of easily accessible sites, such as CSF in patients with
meningitis and persistent joint fluid in those with arthritis, should be required to evaluate
therapeutic response. If follow-up samples are not obtained, the response should either be
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scored as indeterminate or a failure if other signs of progressive or poorly controlled disease
(e.g., multiorgan failure) occur.
The time to assess primary outcomes in candidemia should not just encompass clearance of
blood but also be adequate to detect early recrudescence of candidiasis and mortality directly
or indirectly related to fungal disease. We suggest a period of observation of at least 4 weeks
from the time of enrollment (table 2). In the view of most of the panel members, end-of-therapy
response should be avoided as a primary end point, because the time to stop therapy can be
variable, and end-of-therapy successes will not capture early relapses after discontinuation of
therapy.
Invasive Aspergillosis and Other Mold Diseases
Evaluation of response to therapy in invasive mold disease is difficult. In the highly
immunocompromised patient, fever and localizing physical examination findings are often
absent [25]. In addition, some of the clinical manifestations of IA may not necessarily indicate
clinical deterioration. For example, hemoptysis is more common after neutrophil recovery
[26] and may not signify refractory disease.
Evaluation of radiological responses, particularly at early time points, poses several challenges.
Caillot et al. [27] performed sequential CTs on patients with neutropenia and IA. Despite
administration of effective antifungal treatment, leading to a positive clinical response in most
patients, the median volume of lesions increased 4-fold during the first week of therapy and
remained stable during the second week. This study has implications with regard to the
interpretation of results of salvage therapy in which neutropenic patients with IA could be
enrolled after only 7 days of standard antifungal therapy on the basis of radiological worsening
[8,28–32]. Cavitation coinciding with neutrophil recovery may also be incorrectly equated with
fungal disease progression [27,33–35]. There is inadequate knowledge about the radiological
evolution of IA in nonneutropenic patients who respond to antifungal therapy.
Repeated sampling of infected sites (e.g., repeated lung biopsies) to evaluate for response to
therapy may not be feasible or clinically warranted. In such cases, radiological response can
be equated with control of disease. Other potential problems in assessing outcome are incorrect
diagnosis, mixed fungal diseases [25,36], and coexistent bacterial and fungal diseases or
noninfectious diseases.
Surgery as a therapeutic modality (e.g., for invasive craniofacial mold disease) poses additional
challenges for interpreting therapeutic responses, because it is generally not possible to judge
the effect of drug treatment alone. We suggest judging success or failure at the prespecified
time of analysis, without considering whether surgery was performed. In a secondary analysis,
patients treated with drug alone versus with the drug plus surgery may be analyzed separately.
In addition to facilitating the diagnosis of IA, the galactomannan assay is also a promising
therapeutic marker [13,37–40]. Boutboul et al. [38] showed that serum galactomannan index
(GMI) values significantly increased in patients with IA who did not respond to antifungal
therapy, whereas no significant change occurred in patients who responded to therapy.
Maertens et al. [37] reported that all 24 patients with IA with persistent or increasing serum
GMI values eventually died of or with IA [37]. Woods et al. [41] demonstrated the utility of
serial GMI testing as a predictor of outcome in patients with multiple myeloma and IA. Miceli
et al. [42] defined immune reconstitution inflammatory syndrome (IRIS) as clinical and
radiological deterioration and reduction in serum GMI values coinciding with neutrophil
recovery in patients with IA who subsequently cleared fungal disease without a change in
therapy. Serum GMI has better performance as a diagnostic marker in patients with
hematological malignancies and allogeneic hematopoietic stem cell transplant recipients than
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in solid-organ transplant recipients [43], suggesting that its utility as a therapeutic marker may
also be influenced by host factors.
Anaissie [14] argued that serum GMI values should be used both in practice and in clinical
trials as an early marker of therapeutic response in IA. The majority of panel members
considered serial GMI measurements to be a highly promising therapeutic marker but believed
that it was currently premature to adopt serum GMI value as a primary mycological end point
in clinical trials of IA; serum GMI monitoring should be included as a secondary end point.
Serum (1→3)-β-D-glucan can be a valuable diagnostic adjunct in a number of IFDs, including
invasive candidiasis and aspergillosis [2,44,45]. Data on the utility of serum (1→3)-β-D-glucan
monitoring as a therapeutic marker are limited.
Clinical, radiological, and mycological end points may conflict, particularly at early time points
[9,10]. In the study comparing voriconazole with amphotericin B as primary therapy for IA,
the difference in successful outcomes was apparent by 6 weeks [6]. Most deaths (50 [68%] of
73) that occurred during the first 6 weeks were attributable to IA; of the 25 deaths during the
second 6 weeks, only 6 (24%) were attributed to IA [11]. However, in 2 pooled trials (P041
and P02387) that evaluated posaconazole as salvage therapy for invasive mold diseases, the
overall rate of concordance between treatment responses assessed at 1 and 3 months was only
42% (C. Hardalo, Schering-Plough, personal communication). The concordance between 3-
and 6-month assessments showed substantial improvement (76%).
For primary therapy trials of IA, most of the panel members considered 6 weeks after
enrollment to be the minimum time to assess the primary outcome end point. An analysis at
week 12 or later should be included as a secondary end point. By extrapolation, this period of
observation is reasonable for non-Aspergillus invasive mold diseases. In salvage studies, a time
point of at least 12 weeks should be considered for the primary end point analysis.
Cryptococcal Meningitis
C. neoformans disease most commonly manifests as meningitis. Assessment of treatment
response in cryptococcal meningitis relies on clinical and mycological criteria [46–48].
Documented clearance of CSF typically precedes the expected reduction in antigen titers in
patients with a response to antifungal therapy [46] and is the “gold standard” to evaluate
mycological response. CSF specimens obtained by lumbar puncture are likely to be more
sensitive for recovery of organisms than are those obtained by intraventricular collection; if
the initial lumbar fluid specimen yields positive results followed by a negative ventricular fluid
specimen, no conclusion should be drawn. Clearance of CSF is given more weight than clinical
criteria (e.g., fever and meningismus) in assessing the global response. Thus, clearance of CSF
but persistence of fever or headache should be equated with at least a partial response.
IRIS results from an exuberant inflammatory response toward previously diagnosed infection
or infection with incubating pathogens (e.g., mycobacterial and cytomegalovirus disease). IRIS
is well described in patients with AIDS-associated cryptococcal meningitis after initiation of
antiretroviral therapy and manifests with meningismus and elevated CSF opening pressures,
protein levels, and WBC counts [49–51]. Repeated CSF cultures are required to distinguish
IRIS from persistent or recrudescent cryptococcal disease. IRIS does not represent treatment
failure.
In CNS cryptococcal disease, neurological sequelae, such as blindness and dementia, can
persist indefinitely and are not due to persistent microbes. The absence of fungal disease would
meet the mycological end point for a successful outcome and, in fact, could be equated with
cure of disease. However, the majority of panel members considered a measurable clinical
improvement to be a requisite for a successful outcome in cases of cryptococcal meningitis.
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This approach is consistent with use of primary end points for therapeutic trials of bacterial
meningitis that include neurological sequelae [52–57].
Repeated sampling of CSF is required to assess the therapeutic response, because clinical
symptoms may not correlate with control of disease. Use of systemic corticosteroids and other
immunosuppressive agents may blunt symptoms and signs of meningitis. If an additional CSF
sample is not obtained, then the outcome should be scored as “indeterminate” if a clinical
response occurs and as “failure” if clinical findings are unchanged or worsen. In cases of
concurrent extraneural C. neoformans disease, a mycological response involves documented
clearance of disease from involved sites if repeated sampling is feasible (e.g., blood cultures
for fungemic patients).
Brouwer et al. [58] evaluated antifungal regimens in patients with AIDS-associated
cryptococcal meningitis, using the rate of reduction in CSF colony-forming units within the
first 2 weeks as the primary end point. Despite the low number of subjects, this study identified
amphotericin B plus flucytosine as the most effective regimen. In phase I/II studies in which
patient accrual is limited, such quantitative mycological end points provide valuable data.
However, definitive phase III trials should include longer-term end points and be adequately
powered to evaluate survival, persistent morbidity, and drug toxicity.
Endemic Mycoses
Our guidelines focus on disseminated histoplasmosis and coccidioidomycosis. Chronic
fibrocavitary forms of pulmonary histoplasmosis and coccidioidomycosis may show little
radiological improvement with successful drug therapy. In meningitis, clinical and
mycological evidence of control of disease are requisites of a successful global response.
Radiological resolution of CNS fungal lesions is rarely complete, even after years of
observation. Improvement of CT and MRI findings is a more useful end point to judge success,
with the caveat that improvement in edema can be associated with corticosteroid therapy. IRIS
has been reported in patients with AIDS-associated histoplasmosis receiving antiretroviral
therapy [59] and does not denote treatment failure.
Histoplasmosis
Clearance of blood cultures is the gold standard for mycological response in patients with
histoplasmosis and positive blood culture results. However, blood cultures, including those
that undergo lysis-centrifugation, are too insensitive for results to be used as the sole criterion
to evaluate success. Culture results may be negative before commencement of therapy and may
yield only intermittently positive results during unsuccessful therapy. Thus, clearance of
positive blood cultures is necessary, but not sufficient, to determine whether an outcome is
successful.
Nonculture laboratory markers are useful adjuncts in monitoring the response to systemic
histoplasmosis, with the provision that these tests should be conducted using the same method
and ideally in the same reference laboratory. Although results of the Histoplasma antigen test
has not been used as a study end point in clinical trials, changes in antigen findings have
paralleled those of culture in patients with positive culture results [60–62]. In patients with
histoplasmosis and positive blood culture results, clearance of fungemia is a better measure of
antifungal effect than is clearance of antigen [63]. However, reduction in antigen levels could
be used as a mycological end point in patients with negative blood culture results and as
additional evidence of response in patients with positive culture results. Using a conservative
measure, a decrease in the serum antigen level by at least 50% during the first 3 months of
therapy relative to the baseline level can be equated with a positive mycological response. In
patients whose antigen levels have decrease with therapy, a subsequent increase of ≥ 20% raises
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concern about relapse [64]. Antigen levels were evaluated principally in AIDS-associated
disseminated histoplasmosis; the predictive value of therapeutic response in other patient
populations has not been established. Antigen levels in urine may not decrease for several
weeks, even with effective therapy [65]; therefore, persistent antigenuria should not be equated
with failure of therapy.
Coccidioidomycosis
Several trials of coccidioidomycosis used a composite scoring system to assess therapeutic
response [66–70]. Points were assigned on the basis of (1) symptoms, (2) physical examination
findings, (3) quantitative complement fixation titers (baseline and follow-up titers measured
in the same laboratory concurrently), and (4) culture results. Numerical values were assigned
on the basis of prespecified rules, and the sum of these values at reassessment was compared
with baseline values, with an increasing score indicating deterioration. A successful response
required a >50% reduction in abnormal baseline findings ≤8 months after commencement of
therapy.
For patients with CNS coccidioidomycosis, life-long azole therapy is standard because of the
high frequency of recrudescent disease if therapy is stopped [71,72]. A composite numeric
outcome score using clinical and laboratory abnormalities has been applied to coccidioidal
meningitis [73,74]. In one study, a response was defined as a ≥40% reduction in baseline
abnormalities without subsequent relapse during antifungal treatment [73]. A patient who had
not achieved this level of improvement after 8 months was considered to be a nonresponder.
For coccidioidal meningitis, CSF specimens obtained by lumbar puncture are likely to be more
sensitive for recovery of organisms than are those obtained by intraventricular collection; if
the initial lumbar fluid specimen yields a positive result followed by a negative ventricular
fluid result, no conclusion should be drawn. Moreover, except in the rare patient with
ventriculitis, ventricular fluid findings may provide an overly optimistic picture of the status
of the coccidioidal disease, with lower cell counts, protein levels, and antibody titer levels and
higher glucose values, compared with lumbar or cisternal fluid specimens; this could be
misleading if the scoring system does not repeatedly evaluate the same CSF compartment.
Chronic soft-tissue, bone, and pulmonary disease are also characteristic of coccidioidomycosis.
Some of the original antifungal salvage therapy trials involved patients with persistent
coccidioidomycosis [75]. Therefore, in trials of these forms of coccidioidomycosis,
improvement of clinical and laboratory end points during therapy without eradication of disease
may fulfill the criteria for a successful outcome. A minority of patients with
coccidioidomycosis may require ≥9 months to respond to antifungal therapy [76]; therefore,
extension of the time to evaluate the primary end point to, for example, 12 months is expected
to change the outcome for this subset of patients.
Future Perspectives
To enhance trial efficiency, the US Food and Drug Administration recommended use of
surrogate markers that can substitute for clinical events as tools to increase diagnostic
specificity and to provide objective outcome measures [77]. Future trials involving IFDs—
particularly mold diseases—should include validation of laboratory assays as predictive
correlates of outcome. Such studies will ideally include prespecified serial monitoring of the
marker of interest measured at the same reference laboratory. Future development and
validation of sensitive, non–culture-based laboratory assays (e.g., PCR) and, potentially,
functional imaging modalities (e.g., positron emission tomography [78]) may facilitate both
the early diagnosis of IFD and the assessment of therapeutic response.
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Table 1
General criteria for global responses to antifungal therapy
Outcome, response Criteria
Success
 Complete response Survival within the prespecified period of observation, resolution of all attributable symptoms and signs
of disease and radiological abnormalities, and mycological evidence of eradication of disease
 Partial response Survival within the prespecified period of observation, improvement in attributable symptoms and signs
of disease and radiological abnormalities, and evidence of clearance of cultures or reduction of fungal
burden, as assessed by a quantitative and validated laboratory marker
Failure
 Stable responsea Survival within the prespecified period of observation and minor or no improvement in fungal disease,
but no evidence of progression, as determined on the basis of a composite of clinical, radiological, and
mycological criteria
 Progression of fungal disease Evidence of progressive fungal disease based on a composite of clinical, radiological, and mycological
criteria
 Death Death during the prespecified period of evaluation, regardless of attribution
a
In certain invasive fungal diseases (e.g., invasive mold diseases), stabilization of fungal disease during periods of severe immunocompromise provides
evidence of efficacy of treatment and may be a reasonable short-term therapeutic goal until immune recovery occurs.
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Table 2
Responses to antifungal therapy in patients with candidemia and other forms of invasive candidiasis
Outcome, response Criteria
Success
 Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Documented clearance of pathogen from the blood in cases of candidemia; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., CSF)
If additional cultures are not feasible (e.g., in cases of candidiasis involving visceral organs), survival and
resolution of all attributable symptoms and signs of disease and radiological resolution can be equated with
a complete response
 Partial response Survival and improvement of attributable symptoms and signs of diseasea; plus
Documented clearance of blood in cases of candidemia; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., CSF).
If additional cultures are not feasible, survival and resolution of attributable symptoms and signs of disease
and radiological improvement or stabilization can be equated with a partial responseb
Failure
 Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Persistent isolation of Candida species from blood specimens or specimens from other sterile sites; or
If additional cultures are not feasible, radiological stabilization can be equated with a stable responseb
 Progression of disease Persistent isolation of Candida species from blood specimens or specimens from other sterile sites in
association with worsening clinical symptoms or signs of disease (e.g., septic shock, progression of
hematogenous cutaneous candidiasis); or
New sites of disease or worsening of preexisting lesions radiologically (e.g., those observed in chronic
disseminated candidiasis) in association with clinical deterioration
 Death Death during the prespecified period of evaluation regardless of attribution
NOTE. The minimum period of observation is 4 weeks after start of therapy. The rationale for this minimum period of evaluation is to detect relapses of
disease. Relapse generally requires a positive result of a culture of a specimen of blood or of another sterile site and not simply recurrence of symptoms
or signs (e.g., fever) that are generally nonspecific. In the specific cases of visceral organ involvement (e.g., endocarditis, meningitis, retinitis, or chronic
disseminated candidiasis), we suggest a period of observation of at least 12 weeks after start of therapy.
a
Fever without localizing symptoms or other abnormal physical examination findings is the most common manifestation of candidemia. However, because
fever can result from multiple causes unrelated to candidemia, we suggest that more weight be given to documented clearance of pathogens from the blood
than to resolution of fever in the global assessment of response to therapy. Thus, the scenario of persistent or recurrent fever despite clearance of blood
should be assessed as at least a partial response and, therefore, equated with a successful response.
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b
In visceral candidiasis (e.g., hepatosplenic candidiasis) with negative blood culture results at baseline, persistent fever may be the only attributable clinical
sign of candidiasis, and radiological abnormalities can persist for prolonged periods. In such situations, resolution of fever and stable radiological disease
may be equated with a partial response. Laboratory markers, such as PCR and the (1→3)-β-D-glucan assay, have not been adequately validated as markers
of response to therapy for invasive candidiasis.
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Table 3
Responses to antifungal therapy in patients with invasive mold disease
Outcome, response Criteria
Success
 Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Resolution of radiological lesion(s); persistence of only a scar or postoperative changes can be equated with
a complete radiological response; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., mold disease involving
the palate, sinuses, or cutaneous lesions)
 Partial response Survival and improvement of attributable symptoms and signs of diseasea; plus
At least 25% reduction in diameter of radiological lesion (s); plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., mold disease involving
the palate, sinuses, or cutaneous lesions)
In cases of radiological stabilization (defined as a 0%–25% reduction in the diameter of the lesion),
resolution of all attributable symptoms and signs of fungal disease can be equated with a partial response
In cases of radiological stabilization, biopsy of an infected site (e.g., lung biopsy) showing no evidence of
hyphae and negative culture results can be equated with a partial response
Failure
 Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Radiological stabilization (defined as a 0%–25% reduction in the diameter of the lesion); or
Persistent isolation of mold or histological presence of invasive hyphae in infected sites
 Progression of disease Worsening clinical symptoms or signs of disease; plus
New sites of disease or radiological worsening of preexisting lesions; or
Persistent isolation of mold species from infected sites
 Death Death during the prespecified period of evaluation regardless of attribution
NOTE. The minimum period of observation is at least 6 weeks in trials of primary therapy, but assessment of outcome at week 12 or later should be
included as a secondary end point. For trials of salvage therapy, consider evaluation of the primary end point at least 12 weeks after enrollment.
a
Clear evidence of a radiological response (reduction in diameter by at least 25% with no new sites of disease) should be given more weight than subjective,
nonspecific, or difficult-to-quantify symptoms or signs of disease. Thus, in the scenario of fungal pneumonia, we suggest that radiological improvement
with persistence of fever or cough should be scored as a partial response. Because radiological improvement often lags behind clinical improvement,
especially if a short-term period of evaluation is employed (see Invasive Aspergillosis and Other Mold Diseases), we suggest that radiological stabilization
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and resolution of all attributable symptoms and signs of disease can also be equated with a partial response. See text for discussion of serum galactomannan
index as a promising correlate of therapeutic outcome.
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Table 4
Responses to antifungal therapy in cryptococcal meningitis
Outcome, response Criteria
Success
 Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Documented clearance of pathogen from CSF; plus
Documented clearance of pathogen from blood in cases of bloodstream disease; plus
Documented clearance of pathogen from other sites of disease (if additional cultures are performed); plus
Improvement or stabilization of radiological lesions if present (e.g., CNS cryptococcomaa)
 Partial response Survival and improvement of attributable symptoms and signs of disease; plus
Documented clearance of pathogen from CSF; plus
Documented clearance of pathogen from blood in cases of bloodstream disease; plus
Documented clearance of pathogen from other sites of disease if additional cultures are performed; plus
Improvement or stabilization in radiological lesions if present at baseline
Failure
 Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Persistently positive results of cultures of CSF specimens or specimens of other infected sites
 Progression of disease Worsening clinical symptoms or signs of disease plus
Persistently positive results of cultures of CSF specimens or specimens of other infected sites; or
New sites of disease or worsening of preexisting lesions radiologically
 Death Death during the prespecified period of evaluation, regardless of attribution
NOTE. The minimum period of observation is 10 weeks after the time of initiation of study drug. The rationale for this minimum period of evaluation is
that assessments of clinical and mycological responses may conflict at early time points.
a
Disappearance of cryptococcoma can take years beyond cure of cryptococcal disease. Therefore, a complete or partial response can be assessed despite
persistence of these lesions.
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Table 5
Responses to antifungal therapy in systemic histoplasmosis
Outcome, response Criteria
Success
 Complete response Survival and resolution of all attributable symptoms and signs of disease; plus
Resolution of radiological lesion(s); persistence of only a scar or postoperative changes can be equated with
a complete radiological response; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., blood and CSF)
If infected sites are not accessible to repeat sampling for cultures, clearance of Histoplasma antigen from
serum and urine (if detected at baseline) can be used as a mycological criterion for complete response.
 Partial response Survival and improvement of attributable symptoms and signs of disease; plus
Improvement in radiological lesions; plus
Documented clearance of infected sites that are accessible to repeated sampling (e.g., blood and CSF)
If infected sites are not accessible to repeated sampling for cultures, a decrease in the serum Histoplasma
antigen level of at least 50% during the first 3 months of therapy, relative to the baseline level, can be equated
with a partial mycological response
Failure
 Stable response Survival and minor or no improvement in attributable symptoms and signs of disease; plus
Radiological stabilization; or
Persistently positive results of cultures of specimens from infected sites; or
If infected sites are not accessible to repeated sampling for culture, lack of a decrease in the serum
Histoplasma antigen level of at least 50% after 3 months of therapy can be equated with a stable mycological
response
 Progression of disease Worsening clinical symptoms or signs of disease; plus
New sites of disease or radiological worsening of preexisting lesions; or
Persistently positive results of cultures of specimens from infected sites; or
If infected sites are not accessible to repeated sampling for cultures, an increase in the serum Histoplasma
antigen level of >20% can be a mycological criterion for worsening of disease
 Death Death during the prespecified period of evaluation, regardless of attribution
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NOTE. Three months from time of initiation of study drug is a suggested minimum period of observation for systemic histoplasmosis. Because some
patients develop relapsed disease while receiving antifungal therapy, assessment of outcome at 12 months after initiation of study drug is suggested as a
secondary end point.
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